cycling glp 1 GLP-1s and Cycling: What Riders Need to Know Weight maintenance after discontinuation of
Description
An editorial review of Henry Meds: business model, clinical structure, and how the program compares to PlexusDx Weight Management Protocols
A New Indication for Semaglutide (Wegovy) The injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Wegovy) has been approved by the FDA to reduce the risk of major adverse cardiovascular events (MACE) in adults with established cardiovascular disease (CVD) and either obesity or overweight
In a recent trial, semaglutide led to a 20% reduction in major adverse cardiovascular events (MACE) in patients []
Doctors are recommending it
Numerous risk factors have been noted (such as systemic diseases and medications)
